Phase II Trial of Ivonescimab in High-Risk Localized Clear Cell Renal Cell Cancer
A phase II trial is investigating the efficacy of ivonescimab as a pre-surgical treatment for high-risk localized clear cell renal cell cancer.
Asset / Drug
Drug and asset intelligence for ivonescimab with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
Topline Data
June 28, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.